MA50921A - Sels et formes cristallines d'un modulateur allostérique positif du gabaa - Google Patents
Sels et formes cristallines d'un modulateur allostérique positif du gabaaInfo
- Publication number
- MA50921A MA50921A MA050921A MA50921A MA50921A MA 50921 A MA50921 A MA 50921A MA 050921 A MA050921 A MA 050921A MA 50921 A MA50921 A MA 50921A MA 50921 A MA50921 A MA 50921A
- Authority
- MA
- Morocco
- Prior art keywords
- gabaa
- salts
- crystalline forms
- positive allosteric
- allosteric modulator
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J43/00—Normal steroids having a nitrogen-containing hetero ring spiro-condensed or not condensed with the cyclopenta(a)hydrophenanthrene skeleton
- C07J43/003—Normal steroids having a nitrogen-containing hetero ring spiro-condensed or not condensed with the cyclopenta(a)hydrophenanthrene skeleton not condensed
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pain & Pain Management (AREA)
- Psychiatry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Pyridine Compounds (AREA)
- Steroid Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Liquid Crystal Substances (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862725805P | 2018-08-31 | 2018-08-31 | |
| US16/517,369 US10562930B1 (en) | 2018-08-31 | 2019-07-19 | Salts and crystal forms of GABAA positive allosteric modulator |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MA50921A true MA50921A (fr) | 2020-09-23 |
Family
ID=69528249
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA050921A MA50921A (fr) | 2018-08-31 | 2019-08-30 | Sels et formes cristallines d'un modulateur allostérique positif du gabaa |
Country Status (13)
| Country | Link |
|---|---|
| US (4) | US10562930B1 (enExample) |
| EP (2) | EP3710465B1 (enExample) |
| JP (3) | JP7199739B2 (enExample) |
| KR (1) | KR102845326B1 (enExample) |
| CN (1) | CN113473991A (enExample) |
| AU (1) | AU2019333310B8 (enExample) |
| BR (1) | BR112021003727A2 (enExample) |
| CA (1) | CA3111193A1 (enExample) |
| IL (1) | IL281143B2 (enExample) |
| MA (1) | MA50921A (enExample) |
| MX (1) | MX2021002382A (enExample) |
| TW (2) | TWI850138B (enExample) |
| WO (1) | WO2020047434A1 (enExample) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2016061527A1 (en) * | 2014-10-16 | 2016-04-21 | Sage Therapeutics, Inc. | Compositions and methods for treating cns disorders |
| US10562930B1 (en) | 2018-08-31 | 2020-02-18 | Praxis Precision Medicines, Inc. | Salts and crystal forms of GABAA positive allosteric modulator |
| AU2019397565A1 (en) * | 2018-12-14 | 2021-07-08 | Praxis Precision Medicines, Inc. | Methods for the treatment of depression |
| PE20221911A1 (es) | 2020-03-25 | 2022-12-23 | Sage Therapeutics Inc | Uso de agentes para el tratamiento de condiciones respiratorias |
| WO2022006541A1 (en) * | 2020-07-02 | 2022-01-06 | Praxis Precision Medicines, Inc. | Methods for the treatment of adjustment disorder |
| WO2022177718A1 (en) | 2021-02-18 | 2022-08-25 | Sage Therapeutics, Inc. | Use of neuroactive steroid for treatment of sexual dysfunction |
| JP2024506942A (ja) * | 2021-02-18 | 2024-02-15 | プラクシス プレシジョン メディシンズ， インコーポレイテッド | Ｇａｂａ－ａポジティブアロステリック調節物質のヘミ－クエン酸塩およびその結晶形態 |
| WO2022231309A1 (ko) | 2021-04-27 | 2022-11-03 | 경북대학교 산학협력단 | 저분자 콜라겐을 유효성분으로 포함하는 근감소증의 예방 또는 개선용 식품 조성물 및 약학적 조성물 |
| WO2023159035A1 (en) | 2022-02-16 | 2023-08-24 | Sage Therapeutics, Inc. | Neuroactive steroids for treatment of cns-related disorders |
| WO2023164386A1 (en) * | 2022-02-28 | 2023-08-31 | Sage Therapeutics, Inc. | Neuroactive steroids for treatment of gastrointestinal diseases or conditions |
Family Cites Families (42)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU698834B2 (en) * | 1993-05-24 | 1998-11-12 | Purdue Pharma Ltd. | Methods and compositions for inducing sleep |
| US5939545A (en) | 1994-02-14 | 1999-08-17 | Cocensys, Inc. | Method, compositions, and compounds for allosteric modulation of the gaba receptor by members of the androstane and pregnane series |
| KR19990022323A (ko) | 1995-06-06 | 1999-03-25 | 씨. 랜 낸시 | 안드로스탄 및 프레그난 시리즈의 신경활성 스테로이드 |
| US6780853B1 (en) | 1995-06-06 | 2004-08-24 | Euro-Celtique S.A. | Neuroactive steroids of the androstane and pregnane series |
| WO1998005337A1 (en) | 1996-08-01 | 1998-02-12 | Cocensys, Inc. | Use of gaba and nmda receptor ligands for the treatment of migraine headache |
| YU77701A (sh) | 1999-04-29 | 2005-07-19 | Euro-Celtique S.A. | 3-α-HIDROKSI-3Гџ-METOKSIMETIL-21-HETEROCIKLIČNO SUPSTITUISANI STEROIDI SA ANESTETIČKIM DEJSTVOM |
| CN1688288A (zh) * | 2002-08-05 | 2005-10-26 | 巴克斯特国际公司 | 具有多晶型控制的亚微米粒度颗粒的制备和新多晶型伊曲康唑 |
| WO2004072079A1 (en) | 2003-02-11 | 2004-08-26 | Pfizer Limited | Hydrated and anhydrous sildenafil hemi-citrate compound |
| WO2005007600A2 (en) | 2003-07-11 | 2005-01-27 | Eisai Co., Ltd. | Novel methods using aminobenzoic acid compounds |
| EP1656353B1 (en) | 2003-08-14 | 2010-01-27 | F. Hoffmann-La Roche Ag | Gabanergic modulators |
| WO2005105822A2 (en) | 2004-04-23 | 2005-11-10 | Euro-Celtique S.A. | 3-alpha-hydroxy 21-n- heteroaryl-pregnane derivatives for modulation of brain excitability and a process for the production thereof |
| US20060074059A1 (en) | 2004-08-26 | 2006-04-06 | Goliber Philip A | Isomorphic crystalline habits of 3alpha-hydroxy-21-(1'-imidazolyl)-3beta-methoxymethyl-5alpha-pregnane-20-one |
| EP1888080B1 (en) | 2005-06-09 | 2010-04-14 | Euro-Celtique S.A. | Pharmaceutical compositions of a neuroactive steroid and uses thereof |
| EP1942879A1 (en) | 2005-10-31 | 2008-07-16 | Braincells, Inc. | Gaba receptor mediated modulation of neurogenesis |
| WO2007111880A2 (en) | 2006-03-22 | 2007-10-04 | Mount Sinai School Of Medicine | Intranasal administration of ketamine to treat depression |
| US20090074677A1 (en) | 2007-01-08 | 2009-03-19 | Duke University | Neuroactive steroid compositions and methods of use therefor |
| CN103936716B (zh) * | 2009-04-23 | 2016-09-07 | 施万呼吸有限责任公司 | 具蕈毒碱受体拮抗剂和β2肾上腺素受体激动剂活性的二酰胺化合物 |
| MX2012009821A (es) * | 2010-02-24 | 2012-10-09 | Univ Ramot | Formas cristalinas de la sal de tri-mesilato de perfenazina-gaba y proceso para producirlas. |
| SG190224A1 (en) * | 2010-11-11 | 2013-06-28 | Akron Molecules Gmbh | Compounds and methods for treating pain |
| WO2013006857A1 (en) | 2011-07-07 | 2013-01-10 | The Children's Hospital Of Philadelphia | Genetic alterations associated with autism and the autistic phenotype and methods of use thereof for the diagnosis and treatment of autism |
| PL3024458T3 (pl) | 2013-07-24 | 2018-08-31 | Commissariat à l'énergie atomique et aux énergies alternatives | Zastosowanie flekainidu jako środka anty-koneksynowego oraz sposób wzmacniania efektów działania leku psychotropowego |
| AU2015296117B2 (en) * | 2014-08-01 | 2019-05-16 | Jiangsu Hansoh Pharmaceutical Group Co., Ltd. | Crystalline free bases of C-Met inhibitor or crystalline acid salts thereof, and preparation methods and uses thereof |
| JOP20200195A1 (ar) | 2014-09-08 | 2017-06-16 | Sage Therapeutics Inc | سترويدات وتركيبات نشطة عصبياً، واستخداماتها |
| WO2016061527A1 (en) * | 2014-10-16 | 2016-04-21 | Sage Therapeutics, Inc. | Compositions and methods for treating cns disorders |
| TWI777515B (zh) | 2016-08-18 | 2022-09-11 | 美商愛戴爾製藥股份有限公司 | 治療嗜伊紅性食道炎之方法 |
| US10391105B2 (en) | 2016-09-09 | 2019-08-27 | Marinus Pharmaceuticals Inc. | Methods of treating certain depressive disorders and delirium tremens |
| US10420773B2 (en) | 2017-09-26 | 2019-09-24 | Ovid Therapeutics Inc. | Methods of treating developmental disorders and/or seizure disorders with etifoxine |
| AU2018364659A1 (en) | 2017-11-10 | 2020-05-28 | Marinus Pharmaceuticals, Inc. | Ganaxolone for use in treating genetic epileptic disoders |
| US10562930B1 (en) | 2018-08-31 | 2020-02-18 | Praxis Precision Medicines, Inc. | Salts and crystal forms of GABAA positive allosteric modulator |
| AU2019397565A1 (en) * | 2018-12-14 | 2021-07-08 | Praxis Precision Medicines, Inc. | Methods for the treatment of depression |
| CN113226326B (zh) | 2018-12-17 | 2024-09-20 | 细胞内治疗公司 | 有机化合物 |
| EP3934655A4 (en) | 2019-03-04 | 2022-12-21 | Praxis Precision Medicines, Inc. | PERIMENOPAUSE AND MENOPAUSE TREATMENT METHODS |
| WO2020185710A1 (en) | 2019-03-08 | 2020-09-17 | Alairion, Inc. | Method for treating sleep fragmentation disorders using neurosteroid positive allosteric modulators of the gabaa receptor |
| WO2021025985A1 (en) | 2019-08-02 | 2021-02-11 | Praxis Precision Medicines, Inc. | Methods of treating substance abuse disorder, dyspnea, tinnitus, and child and adolescent depression |
| AU2020358002A1 (en) | 2019-10-02 | 2022-04-21 | Praxis Precision Medicines, Inc. | Combinations of GABA-A receptor positive allosteric modulators and NMDA antagonists, NMDA negative allosteric modulators or NMDA partial agonists |
| WO2021168106A1 (en) | 2020-02-18 | 2021-08-26 | Praxis Precision Medicines, Inc. | Deuterated neurosteroid |
| WO2022006541A1 (en) | 2020-07-02 | 2022-01-06 | Praxis Precision Medicines, Inc. | Methods for the treatment of adjustment disorder |
| WO2022040545A1 (en) | 2020-08-20 | 2022-02-24 | Intra-Cellular Therapies, Inc. | Organic compounds |
| JP2024506942A (ja) | 2021-02-18 | 2024-02-15 | プラクシス プレシジョン メディシンズ， インコーポレイテッド | Ｇａｂａ－ａポジティブアロステリック調節物質のヘミ－クエン酸塩およびその結晶形態 |
| CN117715641A (zh) | 2021-04-26 | 2024-03-15 | 普拉西斯精密医药公司 | 用神经活性类固醇进行治疗的方法 |
| WO2023159094A2 (en) | 2022-02-16 | 2023-08-24 | Praxis Precision Medicines, Inc. | PROCESS OF MAKING 3α-HYDROXY-3β-METHOXYMETHYL-21-(1'- IMIDAZOLYL)-5α-PREGNAN-20-ONE |
| WO2023211856A1 (en) | 2022-04-26 | 2023-11-02 | Praxis Precision Medicines, Inc. | Methods for the treatment of neurological disorders |
-
2019
- 2019-07-19 US US16/517,369 patent/US10562930B1/en active Active
- 2019-08-30 MX MX2021002382A patent/MX2021002382A/es unknown
- 2019-08-30 EP EP19842855.9A patent/EP3710465B1/en active Active
- 2019-08-30 EP EP24194131.9A patent/EP4458357A3/en active Pending
- 2019-08-30 IL IL281143A patent/IL281143B2/en unknown
- 2019-08-30 TW TW112141287A patent/TWI850138B/zh active
- 2019-08-30 AU AU2019333310A patent/AU2019333310B8/en active Active
- 2019-08-30 JP JP2020517339A patent/JP7199739B2/ja active Active
- 2019-08-30 TW TW108131297A patent/TWI823999B/zh active
- 2019-08-30 CA CA3111193A patent/CA3111193A1/en active Pending
- 2019-08-30 CN CN201980071246.9A patent/CN113473991A/zh active Pending
- 2019-08-30 BR BR112021003727-6A patent/BR112021003727A2/pt unknown
- 2019-08-30 KR KR1020217009437A patent/KR102845326B1/ko active Active
- 2019-08-30 MA MA050921A patent/MA50921A/fr unknown
- 2019-08-30 WO PCT/US2019/049103 patent/WO2020047434A1/en not_active Ceased
- 2019-11-27 US US16/698,057 patent/US10927141B2/en active Active
-
2021
- 2021-01-07 US US17/143,602 patent/US20220024967A1/en not_active Abandoned
-
2022
- 2022-12-14 JP JP2022199092A patent/JP2023036708A/ja active Pending
-
2023
- 2023-12-05 US US18/529,117 patent/US12404297B2/en active Active
-
2024
- 2024-10-03 JP JP2024174009A patent/JP2025020120A/ja active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MA50921A (fr) | Sels et formes cristallines d'un modulateur allostérique positif du gabaa | |
| MA52493A (fr) | Sels d'un inhibiteur de fgfr | |
| MA54458A (fr) | Formes cristallines et formes salines d'un inhibiteur de kinase | |
| MA53226A (fr) | Sel et formes cristallines d'omecamtiv mecarbil | |
| DK3844407T3 (da) | Sæt af plader med en mekanisk låseanordning | |
| DK4093980T3 (da) | Sæt af plader med en mekanisk låseanordning | |
| DK4110134T3 (da) | Sæt af plader med en mekanisk låseanordning | |
| EP3870178A4 (en) | Crystalline forms of mnk inhibitors | |
| EP3807279A4 (en) | PHARMACEUTICALLY ACCEPTABLE SALTS OF SEPIAPTERINE | |
| MA42606A (fr) | Sels d'un inhibiteur de lsd1 | |
| EP4178960A4 (en) | SALTS AND FORMS OF A WEE1 INHIBITOR | |
| EP3871221A4 (en) | MODE DEPENDENT HEATING OF A MEMORY DEVICE | |
| EP3353175A4 (en) | SALTS AND SOLID FORMS OF MONOBACTAM ANTIBIOTICS | |
| MA55801A (fr) | Formes solides d'un inhibiteur de glyt1 | |
| MA54638A (fr) | Formes cristallines d'un stimulateur de sgc | |
| MA56001A (fr) | Formes de sel cristallin d'un inhibiteur de kinase | |
| EP3681507A4 (en) | URSO ACID MORPHOLINE AND DIETHANOLAMINE SALTS | |
| IL308750A (en) | Novel salts and crystals | |
| MA54087A (fr) | Sels cristallins d'un inhibiteur de la kallicréine plasmatique | |
| EP3849964A4 (en) | CRYSTALLINE FORMS OF A QUINAZOLE COMPOUND AND ITS HYDROCHLORIDE SALTS | |
| SG11202102110PA (en) | Novel hydrochloride salt forms of a sulfonamide structured kinase inhibitor | |
| EP3887356C0 (en) | MULTICOMPONENT CRYSTALS OF AN ORALLY AVAILABLE HIF PROLYL HYDROXYLASE INHIBITOR | |
| EP3672972A4 (en) | SALT OF A COMPOUND AND CRYSTALLINE FORMS OF IT | |
| EP3977204C0 (de) | Unterwasservorrichtung zur bildaufnahme eines wasserbodens | |
| EP3774733A4 (en) | NEW SALT FORMS OF URAT-1 INHIBITORS |